Represented Alibaba Group in the acquisition of a 33% stake of Ant Financial, operator of China’s biggest online payment platform by market share.
Represented Alibaba Group in relation to Ant Financial’s US$14 billion Series C fundraising, valuing Ant Financial at approximately US$150 billion.
Represented SoftBank Vision Fund’s US$11 billion investment in WeWork.
Represented SoftBank in connection with the additional US$4.6 billion purchase of Didi shares; we also represented SoftBank as sole counsel in its US$4.6 billion investment in Didi.
Represented SoftBank Vision Fund in connection with a US$3 billion investment into Local Services Holding Company, a company established by Alibaba after consolidating the businesses of Ele.me (the food delivery business owned by Alibaba) and Koubei.com (an affiliate company that focuses on bringing local businesses online by providing payment and other technology services); after such consolidation, the valuation of Local Services Holding Company is over US$30 billion.
Represented SoftBank Vision Fund in connection with an investment totaling US$1.5 billion in Chehaoduo, a leading Chinese customer-to-customer auto retail services company that operates Guazi, an e-commerce platform focusing on second-hand car transactions, and Maodou, an e-commerce platform focusing on new car transactions.
Represented Walmart in a US$500 million financing and strategic alliance with New Dada, China’s largest localized, on-demand logistics and grocery O2O e-commerce platform; the transaction included a US$320 million investment by Walmart and a new business cooperation agreement.
Represented Ally Bridge Group in its equity investment in GRAIL, a company developing a blood test that will detect cancer before symptoms appear in order to increase survival rates as compared to those patients with late-stage diagnoses; the investment, led by our client, raised US$300 million in an oversubscribed Series C financing.
Represented Oriente, a Hong Kong-based financial services and technology company, in its US$105 million initial funding round, and a series of recent expansions in Southeast Asia, including two strategic alliances: Cashalo in the Philippines with JG Summit, and Finmas in Indonesia with Sinar Mas.
Represented Trusted Doctors (Xingren) in its strategic merger agreement with Tencent Doctorwork. The newly formed venture, which is named Tencent Trusted Doctors, will offer an ecosystem of both online and offline services devoted to leveraging Internet technology to provide high-quality and accessible healthcare service to customers all over the country.
Represented C-Bridge Capital’s portfolio company Everest Medicines II in its exclusive collaboration, license, and supply agreement with VenatoRx Pharmaceuticals, to support the development and commercialization of cefepime/VNRX-5133 in Greater China, South Korea, and Southeast Asia.
Represented the licensing arm of a French multinational corporation as claimant in a Hong Kong law-governed, Hong Kong-seated HKIAC arbitration with substantial PRC law-governed elements.
Represented a Chinese consumer products manufacturer as respondent in a Hong Kong law-governed, Hong Kong-seated ad hoc arbitration with substantial PRC law-governed elements and in subsequent enforcement proceedings in Hong Kong and Israel courts.
Represented a global industrial gases company as claimant in a PRC law-governed, Shanghai-seated, Chinese-language CIETAC arbitration.
Represented multiple Hong Kong and Chinese clients in high-stakes U.S. litigation proceedings, including civil and criminal trade-secret, and economic espionage litigation, and litigation alleging violations of U.S. state and federal securities laws.
Represented multiple multinational and China-based clients in internal and government investigations involving alleged violations of anti-corruption laws, anti-money-laundering laws, accounting fraud, conflicts of interest, and trade compliance issues.